Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin
Phase of Trial: Phase I
Latest Information Update: 11 May 2017
Price : $35 *
At a glance
- Drugs Epelsiban (Primary) ; Ethinylestradiol/norgestimate; Oxytocin; Oxytocin
- Indications Female infertility
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 13 Jun 2016 Status changed from recruiting to discontinued.
- 21 Apr 2016 Planned End Date changed from 1 Aug 2015 to 1 May 2016.
- 21 Apr 2016 Planned primary completion date changed from 1 Aug 2015 to 1 May 2016.